All In Biotech

Drug Trial Radar · NCT06908954

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

A Phase I, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Palovarotene in Male and Female Participants With Moderate and Severe Hepatic Impairment and Matched Participants With Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Mar 14, 2025

Primary completion

Feb 6, 2026

Study completion Feb 6, 2026

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with normal liver function * Group 2: Participants with moderate liver impairment * Group 3: Participants with severe liver impairment (only enrolled if Group 2 results are safe and acceptable) Blood samples will be taken to assess how the drug binds to proteins in the blood. Participants will undergo various safety checks and procedures. Participants will stay in the clinical unit until Day 5 for these assessments and will return on Day 10 for a final visit.

Conditions

  • Hepatic Impairment
  • Healthy

Interventions

  • PalovaroteneDrug

    A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function

  • PalovaroteneDrug

    A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)

  • PalovaroteneDrug

    A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma drug concentration (Cmax)Time frame: Over 96 hours postdose
  2. Unbound fraction of drug in plasma (fu)Time frame: Over 96 hours postdose
  3. Time to maximum observed plasma concentration (Tmax)Time frame: Over 96 hours postdose
  4. Area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC0-∞)Time frame: Over 96 hours postdose
  5. AUC from 0 to time t corresponding to the last quantifiable concentration (AUC0-tlast)Time frame: Over 96 hours postdose
  6. Apparent terminal elimination half life (T1/2)Time frame: Over 96 hours postdose
  7. Apparent terminal elimination rate constant (λz).Time frame: Over 96 hours postdose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • ERG - Clinical Pharmacology of Miami

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • American Research Corporation/Texas Liver Institute

    San Antonio, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.